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Background: Access to Human Immunodeficiency Virus (HIV) care has been rolled out in Cameroon in the last
decade through decentralised delivery of care and timely initiation of free antiretroviral drugs. We sought to
describe the evolution of mortality and loss to follow up (LTFU) and their patient-related determinants at an HIV
clinic which is facing significant challenges.
Methods: A retrospective review of point of care data from HIV patients was conducted in June 2012 at
Nkongsamba Regional Hospital in Cameroon to establish mortality and LTFU rates. Univariable and multivariable
Cox regression models were used to screen for factors associated with the outcomes. Telephone calls were made
to trace patients LTFU.
Results: Between June 2005 and December 2010, 2388 HIV infected patients were admitted. Of these, 1858 were
aged 15 and above and were included in our analysis. Their median age was 36 years (IQR: 30–44) and they were
followed up over a total risk period of 3647.3 person-years (pyrs). The overall mortality rate was 34.6 deaths per
1000 pyrs (95% CI: 29.0-41.1) while the overall LTFU rate was 94.6 per 1000 pyrs (95%CI: 85.1-105.1).The mortality
rates steadily rose to a peak of 69.6 deaths per 1000 pyrs in 2009 and then fell drastically to 20.6 per 1000 pyrs in
2010. The LTFU rate increased sharply from 29.7 in 2006 to 138.2 in 2007 and remained virtually stable until 2010.
The factors associated with mortality were: being male (aHR = 2.25, 95% CI: 1.58-3.19), clinical disease progression
(aHR = 2.0, 95% CI: 1.58-2.53), CD4 count <200 cells/μl (aHR = 3.14, 95% CI: 1.27-7.73), haemoglobin level <10 g/dl
(aHR = 2.50, 95% CI: 1.69-3.69). Major factors associated with high LTFU rate were: distance to clinic of over 5 km
(aHR = 1.25, 95% CI: 1.00-1.55), being single, having partners with unknown HIV status or taking no treatment and
with CD4 count >500 cells/μl. Two- thirds (66.7%) of traced LTFU patients were dead.
Conclusion: Mortality and LTFU rates in our cohort were high but there is evidence that patients’ outcomes are
improving. Interventions to address factors associated with high mortality and LTFU should be implemented for
optimal results in patient care.
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At the end of 2012, an estimated 35.3 million people
were living with HIV worldwide [1]. Sub-Saharan Africa,
a region with only 12% of the global population remains
the region most heavily affected by HIV accounting for
about 70% of the global burden of HIV. A total of 5.2 mil-
lion deaths have been averted in low- and middle-income
countries between 1996 and 2012 due to increased access
to antiretroviral therapy (ART) [1]. Despite this, however,
mortality from HIV in Sub-Saharan Africa remains very
high especially in the first year; between 8 and 26% of
patients die in the first year of antiretroviral treatment,
with most deaths occurring in the first few months [2].
ART has transformed HIV/AIDS into a chronic illness
and a lifelong follow up for both patients in care and on
ART is mandatory for optimal outcomes. Loss of patients
to follow-up and care (LTFU) is, however, an important
problem in resource-limited settings. A systematic re-
view of published retention rates from ART clinics in
sub-Saharan Africa (SSA) showed that the proportion
of patients retained two years after starting therapy
was approximately 60% [3]. Similarly, in a collaborative
analysis of patients starting ART in 15 treatment pro-
grammes in Africa, Asia, and South America it was found
that 21% of patients were lost to follow-up 6 months after
starting ART [4]. A systematic review and meta-analysis
of studies tracing patients lost to follow-up found that
these patients experience high mortality compared to
patients remaining in care [5]. The successful treatment
of individual patients and the monitoring and evaluation
of ART programmes both depend on regular and complete
patient follow-up.
Cameroon with an estimated population of 19.4 mil-
lion in 2010 [6] had an HIV prevalence rate in 2011 of
4.3% down from 5.5% in 2004 [7]. The ART coverage in-
creased from 36.5% in 2010 to 49.6% in 2011 [8]. The
country HIV Drug Resistance Working Group reported
that the proportion of patients lost to follow up varied
between 7 to 77% across various treatment sites in 2010
with a national average of 33%, higher than the reported
rate (25%) in 2008 [9].A high level of drug resistance
was reported in a cohort of naïve and ART treated pa-
tients infected with HIV-1 only after few years of treat-
ment in Yaounde, Cameroon probably because of high
loss to follow up and poor compliance [10]. In 2005 the
Douala Antiretroviral Initiative (DARVIR) had identified
cost of ARV as the main risk factor for LTFU [11]. Late
presentation and or late ART initiation [12], TB co-
infection [13] and long travels to clinic [14] were the
other important factors for treatment interruption re-
ported by different authors. These studies were mostly
conducted before 2007 during an era of very constrained
access to ARV, and in urban settings. Since 2007 several
changes have been instituted: ARVs are dispensed free ofcharge to patients, many treatment centres have been
established nationwide, treatment has been decentra-
lised, ART initiation cut off has been increased from 200
to 350 and the more toxic stavudine (D4T)-based regi-
men has been gradually phased out since 2010 in ac-
cordance with the 2010 World Health Organisation
(WHO) recommendations [15]. These changes were in-
stituted to improve access to HIV care. Consequently, an
increased number of patients are receiving ART [16,17]
but the outcomes of these patients before and after
these interventions are not known in terms of morbidity
and mortality.
Mortality and Loss to follow up in HIV programs are
on-going challenges to the scaling up of HIV manage-
ment. The rates and determinants of which vary by
health facility [18] and as such each setting needs to de-
termine theirs and institute improvement programs.
This study sought to use routine clinic data to docu-
ment trends in Mortality and Loss to Follow-up in HIV
Care at Nkongsamba regional hospital where the highest




The study was conducted at the Regional Hospital of
Nkongsamba, Moungo Division of the Littoral Region of
Cameroon. It is a 2nd level reference public health facil-
ity with a catchment area of over 321,295 inhabitants.
The HIV clinic was established in 2005 and offers volun-
tary HIV counselling and testing (VCT), ART and lim-
ited community outreach services to patients on ART.
Ethical aspects
The study was approved by the London School of Hygiene
and Tropical Medicine (LSHTM) Ethics Committee. Per-
mission to conduct the study was provided by The Littoral
Regional Delegate for Public Health in Cameroon and The
Director of The Nkongsamba Regional Hospital. It was
not possible or practical to obtain consent from each of
the participants. Since patient identifying data was ab-
stracted, this is considered a low risk.
Definitions
Loss to follow-up: a patient was classified as LTFU if
there was no contact for 90 days after the last missed ap-
pointment for ARV refill. For patients not yet on ART,
180 days of no contact after the last clinical or labora-
tory appointment was considered as LTFU. LTFU is an
early warning indicator for HIV drug resistance. WHO
considers a proportion of LTFU above 20% to be high.
In this study, the LTFU rate was defined as the number
of patients LTFU during the follow up period divided by
the total person-years at risk.
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in care. The mortality rate was defined as the number of
deaths occurring during the follow-up period divided by
the person-years at risk taking into account LTFU and
transfer outs in the denominator.
Inclusion criteria
Adults of both sexes aged 15 years old and above, tested
positive for HIV-1, recruited into the clinic cohort be-
tween 2005 and 2010.
Sample size
A sample size of 680 was needed to detect a 5% differ-
ence in LTFU between the sub-categories of a variable
based upon the national average in 2010 of 33% LTFU.
Study design
We conducted an exploratory retrospective cohort study
of HIV positive patients recruited into the clinic from
20th June 2005 to 31st December 2010 and followed up
till 14th June 2012. In this cohort, the rate of occurrence
of events (deaths and LTFU) was measured over time
and the putative determinants of these events were com-
pared between the group which experienced these events
and the group that did not. Death was ascertained by
relatives who informed the health workers, active tracing
by community health workers or by telephone calls.
Data collection
We used data from the HIV clinic pre-ART and ART
registers and individual patient medical records. The
registers were designed by the National AIDS Control
Committee (NACC) for the standardised collection and
reporting of data. From pre-ART and ART registers, we
counted the number of patients ever enrolled in care,
the number initiated on ART and cotrimoxazole prophy-
laxis, their dates of ART initiation, the type of regimen,
drug refill dates and the patient status. The medical re-
cords were designed by the hospital and are stored in
the clinic’s records office by year of recruitment, by
codes and by patient outcome.
From each of the patient’s medical records we ab-
stracted the following information: socio-demographic
characteristics which were telephone contact numbers,
date of birth, gender, place of residence, occupation, in-
surance scheme, religion, distance to clinic, alcohol and
tobacco consumption, education and matrimonial status.
Clinical features including date of HIV diagnosis, base-
line weight and height, disease and clinical stage at pres-
entation were also collected. Laboratory parameters at
baseline and during follow-up such as CD4 count,
haemoglobin level, liver transaminases, fasting blood
sugar, creatinine and urine albumin levels were also
used. Treatment related variables including date of ARTinitiation, first line ART regimen, drug side effects, cotri-
moxazole prophylaxis and alternative therapies were
noted. Outcome measures of interest included date of exit
from the cohort, the nature of the event marking the exit
be it death, transfer out, loss to follow up or continuing
care till 14th June 2012, the day of censorship.
Treatment registers were used to ascertain the last day
a patient was seen in the clinic. We dialled the available
phone numbers and where reachable, we proceeded to
find out if they were alive, dead and date of death, if
alive and taking treatment elsewhere or not, reasons for
defaulting and then advised them to return to care were
appropriate. These variables were entered electronically
into a questionnaire created using the Epidata® software
version 3.1. The final dataset with variables of interest
was exported to Stata® software for analysis.
Data analysis
Data analyses were performed using Stata® 12.1(Stata-
Corp LP, TX77845, USA). The data set was checked for
logical inconsistencies, illegal codes, omissions and im-
probabilities by tabulating, summarising, describing and
plotting variables. Missing observations were excluded
where they constituted a small random proportion but
were included if they were found to be differential
amongst subgroups.
Our outcomes of interest were deaths and LTFU ana-
lysed as time-to-event variables. Putative risk factors of
interest for Mortality and LTFU, how they were treated
or recoded and the rationale for categorisation are pre-
sented in Table 1. Age, year of enrolment and gender
were considered a priori confounders. No effect modifi-
cation between variables was considered.
Summary statistics were presented as proportions for
categorical variables and as means (standard deviations) or
medians (IQR-Interquartile Range) for continuous vari-
ables. Pearson Chi-square analyses were used to examine
the difference in proportion of deaths and LTFU between
the various subgroups created in Table 1. A t-test was used
for the difference between means in two subgroups.
Kaplan-Meier survival curves were used to display the risk
of mortality and LTFU over the study period. Classical co-
hort analysis was used to obtain Mortality and LTFU rates
and their 95% confidence intervals (95%CI). These rates
were plotted to display the trend over the years. A univari-
able Cox regression model was set up to screen for factors
associated with Mortality and LTFU. Crude hazard ratios
(HR) and their 95%CI were obtained. The p-values for hy-
potheses testing were calculated from likelihood ratio tests
(LRT). A test for linearity and departure from linearity
was performed for ordered categorical variables. Variables
found to be associated at 5% confidence level, with Mor-
tality and LTFU were included in a multivariable Cox
model to adjust for the effects of gender, current age and
Table 1 Categorisation of explanatory variables
Factor Type of variable and categorisation Rationale for categorisation
Calendar year of entry Ordered categorical: Events, program performances usually vary with time
2005, 2006, 2007, 2008, 2009, 2010
Current age groups (years) Ordered categorical: 15 – 24, 25 – 34, 35 – 44 , >45
(using Lexis expansion)
Events vary with age and adjusting for age attained in cohort is more appropriate
than by age at entry as this avoids residual confounding
Gender Binary: Females, Males Gender is usually associated with most diseases and thus a strong confounder
Region or province Unordered categorical: Littoral, South-West, West, Other Risk of clustering of events by place of residence
Marital status Unordered categorical: Single, Monogamous, polygamous,
divorced, widowed
Socio-cultural and economic empowerment is usually differential in African context
Partner HIV Status Unordered categorical: Negative Health seeking behaviour, adherence, treatment success or failure may be determined
by partner HIV status, viral load and viral strain
Positive but not taking ART, Positive and taking ART,Unknown
Occupation Binary: Lower grade, higher grade Proxy measure of level of socio-economic status. Grading based on International
Standard Classification of Occupations (ISCO)
Distance(km) Binary: ≤5, >5 Usual walking distance within 30 minutes to health facility is 5 km (indicator of
accessibility); also reflects the population living in the urban centre and usually
accessible to community workers
Alcohol Intake Binary: No, Yes Interaction with drugs, co-morbidity, behaviour change
Smoking Binary: No, Yes Factor of many co-morbid conditions
WHO Clinical Stage Ordered categorical: Risk of death and health care seeking behaviour is influenced by the severity of
disease usually; the staging also guides when to start ART




Immune deficiency Ordered categorical: based on CD4 count Risk of opportunistic infection and thus death depend on CD4 count; initiation





Haemoglobin level (g/dl) Binary: <10, ≥10 Cut off point based on the median value in this HIV cohort to define anaemia
Alanine amino-Transferase, ALAT (IU/l) Binary: <50 , ≥50 Cut off point as determined by the hospital laboratory
Above which indicates liver injury (more specific marker)
Aspartate amino-Transferase, ASAT (IU/l) Binary: <45, ≥45 Cut off point as determined the hospital laboratory
Above which indicates liver injury(less specific marker)



















Table 1 Categorisation of explanatory variables (Continued)
Creatinine level(mg/l) Binary: ≤15, >15 Cut off point as determined the hospital laboratory
Above which indicates kidney injury
NNRTI Regimen Binary: EFV(efavirenz)-based, NVP(nevirapine)-based EFV or NVP is present in all first line regimens; their relative efficacy, tolerance or
toxicity may be relevant
NRTI Regimen Unordered categorical: ABC(abacavir)/TDF(tenofovir)-based,
AZT(zidovudine)-based,
NRTI form the backbone of all first line regimens; while 3TC is invariably present, the
relative toxicity, efficacy and tolerance may be relevant to adherence and emergence
of drug resistance and thus to Mortality and LTFU
D4T(stavudine)-based, None (missing value)
Drug Change Binary: No, Yes Proxy measure for the presence of drug toxicity (usually) or drug resistance (rarely)
Cotrimoxazole Prophylaxis Binary: No, Yes Measure to prevent common opportunistic infections
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time was assessed graphically using Aalen plots. Where
the model could not converge due to collinearity, the vari-
ables responsible were taken out of the model.
From the established list of LTFU patients, we counted
the number that could be traced, their ultimate out-
comes and reasons for dropping out. The results were
presented as proportions. Similarly, the number of pa-
tients ever enrolled and those who ever started ART was
presented graphically as absolute numbers.
Results
Participants
Results for 1858 adults are presented. Of these 1305
(70.2%) were females. Most patients 483 (26.5%) were re-
cruited in the year 2008. The median age at presentation
was 36 years (IQR: 16–70). A total of 3647.3 person-years
of observation are reported. The majority of them (92.3%)
were residing in the Littoral Region but just 43.5% had to
travel 5 km or less to the clinic (Table 2). About 52% of
them were peasant farmers and only 7% were currently in-
volved in a high grade job. Sixty two per cent (1095) of pa-
tients were in WHO Clinical Stage III and IV, they had a
median baseline CD4 count of 201 cells/μl (IQR: 92–304)
and a baseline median haemoglobin level of 10.9 g/dl
(IQR: 9.2-12.5).
The three commonest modes of presentation were, con-
stitutional syndrome [unexplained wasting, fever and diar-
rhoea for over 1 month] (29%), chest infections including
tuberculosis (20%) and referral from antenatal clinics
(13%). At least 95% of patients had normal baseline liver
transaminases while 82.8% of patients had a normal cre-
atinine level of <15 mg/l. The proportion of patients who
had not yet started ART was 35.6% meanwhile among
those on ART, about two out of three were on nevirapine-
based regimens and just over a half (53.5%) were taking
stavudine-based regimens. Only 1% was placed on either
abacavir- or tenofovir –based therapies. Over two-thirds
of patients on treatment did not experience a drug substi-
tution for any reason. Almost 95% of the whole cohort
was receiving cotrimoxazole prophylaxis.
Outcome assessment
Over the seven-year follow up period, amongst the 1858
enrolled, 192(10.3%) were confirmed dead, 680(36.6%)
had been LTFU, 165(8.9%) were confirmed to have been
transferred out meanwhile 821(44.2%) were still continu-
ing care by June 2012 (Figure 1).
The survival probabilities over time and the risks of
LTFU over time as displayed by Kaplan-Meier curves
(Figures 2 and 3 respectively), show that the risk of
LTFU in the first 12 months in care is above 20% while
the risk of death within two years of enrolment is
about 10%.The overall mortality rate was 34.6 deaths per 1000
person-years (95%CI: 29.0-41.1). This rate initially dropped
between 2005 and 2006 then increased gradually from 2006
to 2009 (from 24.6 to 69.6) before decreasing in 2010 to
20.6 per 1000 pyrs.
The overall LTFU rate was 94.6 per 1000 person-years
(95%CI: 85.12-105.12). It increased sharply from 29.7 in
2006 to 138.2 in 2007 and remained virtually stable until
2010. Both Mortality and LTFU rates broadly reflect the
trend in enrolment and ART initiation during the same
time frame (Figure 4).
Predictors of mortality
In univariable analysis, the mortality rate was just over
two times higher in men than in women HR = 2.25(95%
CI: 1.58-3.19, p < 0.0001) and the age group 25–45 years
was most affected by death. Patients living more than
5 km from the clinic had a 38% reduction in mortality
compared to those living within 5 km to the clinic HR =
0.62(95%CI:0.43-0.88, p < 0.007). Patients with late clinical
presentation (stages III and IV) had the poorest outcomes.
The rate of death doubled from one clinical stage to an-
other (HR = 2.0, 95%CI: 1.58-2.53; LRT for linearity, X2 on
2df, p = 0.30) showing a dose–response effect. The mortal-
ity rate was highest in those with severe immune defi-
ciency, those with anaemia (HR = 1.99, 95%CI: 1.37-2.87)
and those who smoked (HR = 2.06, 95%CI: 1.37-3.08).
However, patients treated with a nevirapine-based regimen
(HR = 0.37, 95%CI: 0.25-0.56, p < 0.0001) and those whose
treatment was ever changed (HR < 0.01, p < 0.0001) had
better outcomes. There was no association between mor-
tality and either marital status, partner HIV status, socio-
economic status, alcohol intake, liver and kidney function
abnormalities, type of NRTI drug used or cotrimoxazole
preventive therapy (CPT) use. In multivariable analysis
(Table 3), distance to clinic (aHR = 0.60, 95%CI: 0.42-0.86),
clinical stage and immunological status, low haemoglobin
(aHR = 2.50, 95%CI: 1.69-3.69), and choice of NNRTI drug
remained significantly associated with mortality after
adjusting for gender, current age and time.
Predictors of loss to follow up
In univariable analysis, we found an association between
LTFU and year of recruitment, place of residence, marital
and partner HIV status, CD4 count, and ART regimen
and cotrimoxazole prophylaxis. However, after adjusting
for time spent in cohort (Table 4), place of residence,
marital status and partner’s HIV status were associated
with LTFU but with no clear pattern or direction of effect.
Living more than 5 km away from the clinic (aHR = 1.25,
p = 0.01) was associated with a higher risk of LTFU.
Receiving ART was linked to a 25 – 81% chance of LTFU
depending on the ARV regimen. Meanwhile, receiving
cotrimoxazole prophylaxis (aHR = 0.47, p < 0.0001), having
Table 2 Baseline characteristics of patients
Factor Number Factor Number
N (%) N (%)
Calendar year
2005 103(5.7) Immune deficiency
2006 208(11.4) None 234(13.4)
2007 401(22.0) Mild 186(10.7)
2008 483(26.5) Moderate 449(25.8)
2009 351(19.2) Severe 871(50.1)
2010 278(15.2) Total 1740(100.0)
Total 1824(100.0)
Current age groups (years)
15 – 24 Haemoglobin level(g/dl)
25 – 34 > = 10 848(61.1)
35 – 44 671(36.3) <10 539(38.9)





Males 540(29.6) <50 1344(98.3)




South-West 44(2.4) <45 1311(95.9)
West 79(4.4) > = 45 56(4.1)
Other 16(0.9) Total 1367(100.0)
Total 1800(100.0)
Marital status
Single 568(31.8) Fasting blood sugar(mg/dl)
Monogamous 636(35.6) <126 996(94.1)
Polygamous 152(8.5) > = 126 62(5.9)




Negative 217(12.1) Creatinine level(mg/l)
Positive-ART 220(12.2) <=15 125(82.8)
Positive + ART 99(5.5) >15 26(17.2)
Unknown 1262(70.2) Total 151(100.0)
Total 1798(100.0)
Occupation NNRTI Regimen
Lower grade 1668(93.0) EFV-based 395(33.7)
Higher grade 126(7.0) NVP-based 779(66.3)
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Table 2 Baseline characteristics of patients (Continued)
Total 1794(100) Total 1174(100.0)
NRTI Regimen
Distance(km)
≤5 781(43.5) ABC/TDF-based 19(1.0)
>5 1015(56.5) AZT-based 527(28.9)




No 687(39.0) No 804(68.3)
Yes 1077(61.0) Yes 374(31.7)
Total 1764(100.0) Total 1178(100.0)
Smoking Cotrimoxazole use
No 1495(84.7) No 72(5.4)
Yes 269(15.3) Yes 1251(94.6)







Figure 1 Cohort construction of participants enrolled between 2005 and 2010.
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Figure 2 Kaplan-Meier curve of cumulative probability of death.
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receiving a nevirapine-based regimen (aHR = 0.75, p = 0.04)
were associated with a reduction in the rate of LTFU.
Outcome of patients lost to follow up
Amongst the persons LTFU, only 20.8% could be traced
of which two-thirds were confirmed by relatives to have
died. The majority (85.4%) of those still alive ( including
those who were receiving and not receiving ART) were
not motivated to turn up for their appointments but all


























Figure 3 Kaplan-Meier curve of cumulative probability of loss to folloDiscussion
This study has demonstrated high rates of mortality and
LTFU in the early years of the program but has also
shown a trend towards reduction over the years. Mortality
of HIV-infected patient was 28.3 per 1000 pyrs in 2005,
increased to 69.6 per 1000 pyrs in 2009 and then sharply
decreased to 20.6 per 1000 pyrs in 2010.This trend was
also documented for LTFU. The rate at the start of the
program in 2005 was 56.6 per 1000 pyrs, rose to 138.2 per
1000 pyrs in 2007 before gradually showing a gradual re-
duction to a rate of 96.3 per 1000 pyrs in 2010.4 6 8
hort (years)
w-up.
Figure 4 Trends in enrolment into care, Initiation on ART, LTFU and Mortality.
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The number of people under HIV care and ART in-
creased tremendously in the year 2007 which marked
the beginning of free ARV, reduction in the cost of base-
line laboratory tests and at a time when the Nkong-
samba Regional Hospital was the only HIV clinic in the
municipality and its environs. The steady fall in the
number of people enrolled from 2008–2010 may be due
to the further expansion of the ART program to nearby
district hospitals and a fall in the prevalence of HIV in
the country [7]. The second peak in 2011 may be the re-
sult of the revision of National and WHO guidelines in
2010 whose main highlight was early ART initiation [15].
This period was also marked by a renewed and substantial
support to the country program by the Global Fund. The
enrolment data in 2005 and 2012 are truncated.
This increase in access to care is universal and is asso-
ciated with a decrease in the number AIDS-related
deaths but with variations from one region to another
[19]. In this study, the Mortality and LTFU rates be-
tween 2005 and 2010 mimic the trend in enrolment
overall, but with some variation. The poor performance
can be due to the increase in the number of patients in a
resource constraint setting. It is important to note that,
this cohort of patients in the clinic is in the hands of
three dedicated nurses and two community relay agents.
The doctors, pharmacy clerks and laboratory technicians
only dedicate part of their time to the HIV clinic as they
equally attend to all patients seen daily in the hospital for
other conditions. Between 2008 and 2009, drugs and la-
boratory reagents stock out were frequent and the activityof community workers suspended. This could explain why
LTFU and mortality were at their peaks. In 2009, the pro-
gram was hit by a financial crisis after the country failed to
qualify for funding from the Global Fund. It is not clear if
the peak in Mortality and LTFU rates in 2009 could be
linked to the crisis as data from other clinics in the coun-
try are not available for comparison. The improvement
observed in 2010 may just reflect a fall in enrolment or a
real impact from renewed national and multilateral effort.
These system-related factors are not examined in this study
but as actors in the health care system, it is our opinion
and can be a plausible explanation of the trend observed. A
study to examine these structural and contextual factors
might be advisable just as would be extending the current
study to measure the rates in 2011 and 2012 to see if the
rates continue to decrease as observed from 2010.
Although the LTFU as a proportion or risk is high
(36.33%) in 2010, it is far below the 77% reported by Bil-
long et al. in 2010 from the same clinic [9]. Our LTFU rate
for 2010 was 96.29 per 1000 person-years. A rate may be
the appropriate measure of incidence since patients are en-
rolled at different times (staggered entry) and have differ-
ent risk periods. Though the difference in approach may
lead to different results, we strongly believe that, our esti-
mate is more plausible. Our Mortality and LTFU rates al-
though corrected for time spent in cohort, may be limited
by measurement bias owing to transfer outs, incomplete
ascertainment of the outcome of patients LTFU, survival
estimates not corrected for LTFU [20,21] and the absence
of sensitivity analysis for our regression model. The effect
on our estimates will likely be an underestimation.
Table 3 Factors independently associated with mortality
Factor Crude hazard ratios
(95% Confidence intervals)




≤5 1.00 0.007 1.00
>5 0.62 (0.43-0.88) 0.60 (0.42-0.86) 0.005
Gender
Females 1.00 <0.0001 1.00
Males 2.25 (1.35-3.19) 2.25 (1.35-3.19) <0.0001
Smoking
No 1.00 0.001 1.00




II 1.18 (0.48-2.91) <0.0001 1.18 (0.47-2.93) <0.0001
III 3.77 (1.95-7.26) 3.55 (1.82-6.91)
IV 6.38 (2.99-13.63) 6.13 (2.82-13.29)
Immune deficiency
None 1.00 <0.0001 1.00
Mild 1.07 (0.31-3.70) 1.13 (0.33-3.91)
Moderate 0.88 (0.32-2.43) 0.81 (0.29-2.25) <0.0001
Severe 3.62 (1.48-8.90) 3.14 (1.27-7.73)
Haemoglobin
level(g/dl)
≥10 1.00 0.0003 1.00
<10 1.99 (1.37-2.87) 2.50 (1.69-3.69) <0.0001
NNRTI Regimen 1.00
EFV-based 1.00 <0.0001 0.40 (0.26-0.61) <0.0001
NVP-based 0.37 (0.25-0.56)
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This study identified age, sex, calendar year, distance to
clinic, clinical and immune status at presentation, low
baseline haemoglobin concentration, choice of NNRTI
(Non-Nucleotide Reverse Transcriptase) drug and drug
substitution to be strongly associated with mortality.
Age is often associated with diseases and death. The
age group 25–45 had the highest mortality rate probably
because the disease is more common in this age bracket,
the sexually active population. Men experienced more
deaths than women though more women were affected
by the disease. A likely explanation for this may be due to
the fact that older men were significantly more affected by
disease compared to women (mean age of 41.6 years for
men against 35.9 years for women) and men presented at a
later stage than women (68% of men against 59% women
presented with advanced disease). Women present early
owing to antenatal care referrals. Patients living within5 km of the clinic had a higher mortality rate than those
further away. The evidence was however weak and this
could be due to the fact that this category of the population
who live in the urban centre of Nkongsamba came to die in
the hospital leading to increased ascertainment of their out-
come compared to the distant rural population who mostly
die at home (ascertainment bias). This argument is further
supported in this study by the evidence that the LTFU rate
was higher in those from rural areas. If our results are valid,
then the likely explanation for the observation that those
living closer to the hospital suffered more deaths could be
that they may be less adherent to treatment due to fear of
stigma from users and health workers familiar to them. A
more complete investigation into the outcome of patients
LTFU might help reduce this ascertainment bias. It is well
known that the natural history of HIV/AIDS follows the
clinical and immunological stages with more deaths oc-
curring at later stages. Late presentation was common
Table 4 Adjusted risk ratios for factors independently associated with LTFU
Factor Unadjusted Cox hazard ratios P-values from LRT Adjusted hazard ratios P-values




2007 1.69(1.05-2.72) 0.94(0.57-1.55) <0.0001




15 – 24 1.00 1.00
25 – 34 0.62(0.43-0.89) 0.06 0.67(0.46-0.97)




South-West 1.29(0.67-2.50) 0.02 1.32(0.33-5.32)















>5 1.22(0.98-1.51) 0.07 1.25(1.00-1.55) 0.01
NNRTI Regimen
EFV-based 1.00 1.00 0.04
NVP-based 0.77(0.59-1.01) 0.06 0.75(0.57-0.99)
NRTI Regimen
ABC/TDF-based 0.13(0.02-0.93) 0.19(0.03-1.39)
AZT-based 0.64(0.49-0.83) <0.0001 0.59(0.45-0.77)




Mild 0.76(0.51-1.14) <0.0001 0.75(0.50-1.13) <0.0001
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Yes 0.07(0.04-0.12) <0.0001 0.07(0.04-0.12) <0.0001
Cotrimoxazole
Prophylaxis
No 1.00 0.004 1.00 <0.0001
Yes 0.45(0.30-0.75) 0.47(0.30-0.74)
*adjusted for time and place of residence **adjusted for each other and time.
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study is a driving force for mortality. A low haemoglobin
concentration (anaemia) was another major factor con-
tributing to more deaths. Low haemoglobin is related to
chronic inflammation owing to HIV per se but is fur-
ther compounded by poor nutrition and concurrent
parasitic infestations including intestinal worms and
malaria that are common in Africa [22]. Correcting severe
anaemia (haemoglobin < 8 g/dl) is indispensable before the
start of ART. This correction is done in clinical practice by
blood transfusion and or prolonged nutritional support and
supplementation with haematinics. The time and money
necessary for treating anaemia adds to the misery of
patients already heavily afflicted. Smoking though strongly
associated with mortality in univariable analysis, its ef-
fect was confounded by gender as smokers were mainly
men (76%). Many smokers also may have stopped
smoking at the time of this study as a result of illness.Figure 5 Outcome of patients lost to follow-up.Patients taking Nevirapine (NVP) in their combination of
drugs had better outcomes than those on Efavirenz (EFV)
[HR = 0.4(0.26-0.61), p < 0.0001]. This result is contrary to
an accumulation of evidence indicating that EFV has a
superior efficacy and tolerability compared to NVP [23-25].
Our results might be attributed to the fact that EFV is
more expensive and was usually recommended to the
subgroup of patients with severe disease who had a
higher risk of death. EFV was contraindicated in women
who were pregnant or who planned to become preg-
nant. (EFV is recently recommended in pregnant women
[WHO 2012 update]) [26]. Patients who had one or
more drugs in their combination substituted had better
outcomes. Drug substitution was done in an event of
severe side effects so much so that in 2010–2011 all
patients on Stavudine (D4T) were switched to either
Zidovudine or Tenofovir in line with the WHO 2010
guidelines recommending the phasing out of D4T [15].
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changes per se as the close monitoring these patients
(with side effects) received is likely to have impacted
on their outcomes.
Other baseline laboratory tests (transaminases, blood
sugar and creatinine) were not associated with survival.
These indicators are not linked to HIV pathology but
used to monitor or guide treatment. Given that they
constitute a financial barrier to the initiation of ART and
are not directly associated with AIDS-related deaths, it
might be necessary to either drop them or use them in a
case by case scenario. Alcohol intake is widespread and
most of the patients (61%) in the cohort used alcohol.
Categorising alcohol intake into units of consumption
and assessing these could be a more useful indicator.
Cotrimoxazole reduces the risk of bacterial infections
and malaria in persons living with HIV [27] and was
given free of charge to a majority of patients and this
explains why it was not associated with mortality in this
study. Although evidence for an association between part-
ner HIV status, marital status and mortality was very
weak, it is however plausible that patients whose partners
are receiving ART do have better outcomes because of
mutual assistance to improve adherence and thus reduced
risk of emergence of drug resistance. Similarly, matrimo-
nial status was not a determinant but it is plausible that
those engaged in polygamous marriages had poorer out-
comes probably due to cross infection and re-infection.
Those living out of the littoral region in which the clinic is
based also had poorer survival outcomes and this might
be as a result of distance although there was no evidence
in favour of region of residence as a factor.
Determinants of loss to follow up
Factors for which there was suggestive or strong evi-
dence for an association with LTFU after adjusting for
time in cohort include calendar year (proxy for number
enrolled), region of residence, distance to clinic, marital
and partner HIV status, ART and cotrimoxazole preven-
tion therapy ( CPT).
It is probable that persons living further from a health fa-
cility will have less access to health care because they have
to put in an extra financial and motivational effort. Patients
living closer to and at walking distance from the health fa-
cility were less likely to discontinue follow up care. Simi-
larly, patients residing in regions out of the Littoral Region
in which our clinic is situated were more likely to drop out.
Our findings are consistent with an earlier study in the
South West Region of Cameroon [14]. However, those liv-
ing in the furthest regions appear to have better retention
rates. This is unusual and the likely explanation may be
that, they constitute a minority subgroup mostly workers
who originate from a locality close to the clinic but because
they live very far away, their appointments for drug refillare spaced out to up to three months. This preferential
treatment sounds unethical, but it is a strategy used and ac-
cepted locally to reduce transport cost and job absenteeism
for these far-distant patients. Patients receiving any form of
treatment (ART and or CPT) from the clinic were more
likely to remain in care. Patients with advanced or severe
immune deficiency were more likely to remain in care
probably because they themselves and even health workers
were too concerned by their illness and were usually those
on both ART and CPT. Similarly, patients with mild or no
immune suppression may believe they are not too sick to
seek regular attention about their health and thus more
likely to lose contact with the health facility. This raises
concerns about patient education or counselling on asymp-
tomatic HIV disease.
Though evidence for an association between age and
LTFU was weak, it is nonetheless plausible to observe that
the youngest age group is most likely to drop out because
they are usually asymptomatic at presentation and conse-
quently not too much worried about their present condi-
tion. Age was likely to be confounded by disease stage.
Outcome of patients lost to follow up
A phone call was the optimal means of reaching and tra-
cing patients LTFU (the use of community workers was an
alternative but prohibitively expensive). Given that half of
the 402 patients with no phone contacts were those LTFU
and that up to 66.7% of those LTFU for whom information
was available were already dead, it is likely therefore that
there was significant mortality even among those who
could not be traced. This excess mortality should be
accounted for in calculating mortality rates [20,21]. The
likely impact of LTFU to our estimate for mortality is
therefore an underestimation of the true value but it is un-
likely to affect the predictors except were ascertainment of
outcome differed amongst the subgroups (when LTFU is
itself the real factor responsible for mortality).
The major reason for defaulting was lack of personal
motivation. After our conversation with them, they all
promised to return to care. Extending this study for a
couple of months would investigate if they did indeed
return. Patient education on the necessity for a lifelong
and regular care is therefore crucial. Given that the
clinic has a limited human resource, a mass or group
education of these patients will appear to be the cost-
effective means of going around this obstacle. Four of
them were receiving alternative remedies from trad-
itional practitioners. Traditional medicine is a common
but a disorganised practice in the country. It is likely
that many more are using alternative therapy even those
in care but data on this practice was not routinely col-
lected by health workers. Over 80% of Africans do rely
on traditional medicine or indigenous knowledge to
meet their health needs for one or another reason [28].
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care in this cohort. Financial problems were less of an
issue given that many aspects of care have become free
of charge compared to the era before 2007 [14].
This study had a couple of draw-backs that may im-
pact on its quality. Its retrospective design made it liable
to incompleteness of information collected. The mortal-
ity and LTFU rates calculated are an underestimation of
the expected. Our data are hospital-based thus making it
somehow difficult to tell if our results can be extrapo-
lated to the general population. The study however can
be credited for its relatively sufficient sample size and its
cohort design that allows calculating incidence of mor-
tality and LTFU.
Conclusion
Access to HIV care has been scaled up in recent years
but the outcome of patients in terms of mortality and
loss to follow up our clinic is only beginning to improve
since 2010. An extension of the study for a couple of
years is necessary to confirm the down trend in Mortal-
ity and LTFU. Men, late presentation, anaemia and drug
regimen were the main factors strongly associated with
mortality while the number of patients enrolled and how
they were monitored were the major determinants of
LTFU. While patients need to be motivated to present at
an early stage and continue a lifelong follow up, inter-
ventions to address factors associated with high mortal-
ity and LTFU should be implemented for optimal results
in patient care.
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